Elizabeth Adams1, Pauline Genter2, Emma Keefe3, Kevin Sandow3, Virginia Gray4, Jerome I Rotter3, Yii-Der Ida Chen3, Eli Ipp3. 1. California State University, Long Beach, CA, United States; Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA, United States. 2. Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA, United States. Electronic address: pgenter@labiomed.org. 3. Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA, United States. 4. California State University, Long Beach, CA, United States.
Abstract
AIMS: Glucagon-like peptide-1 (GLP-1) contributes to insulin secretion after meals. Though Hispanics have increased risk for type 2 diabetes mellitus, it is unknown if impaired GLP-1 secretion contributes to this risk. We therefore studied plasma GLP-1 secretion and action in Hispanic adults. METHODS: Hispanic (H; n = 31) and non-Hispanic (nH; n = 15) participants underwent an oral glucose tolerance test (OGTT). All participants were categorized by glucose tolerance into four groups: normal glucose tolerant non-Hispanic (NGT-nH; n = 15), normal glucose tolerant Hispanic (NGT-H; n = 12), impaired glucose tolerant Hispanic (IGT-H; n = 11), or newly diagnosed type 2 diabetes mellitus, Hispanic (T2D-H; n = 8). RESULTS: Glucose-induced increments in plasma GLP-1 (Δ-GLP-1) were not different in NGT-H and NGT-nH (p = .38), nor amongst Hispanic subgroups with varying degrees of glucose homeostasis (p = .6). In contrast, the insulinogenic index in T2D-H group was lower than the other groups (p = .016). Subjects with abnormal glucose homeostasis (AGH), i.e., T2D-H plus IGT-H, had a diminished glucagon suppression index compared to patients with normal glucose homeostasis (NGT-H plus NGT-nH) (p = .035). CONCLUSIONS: GLP-1 responses to glucose were similar in Hispanic and Non-Hispanic NGT. Despite similar glucose-induced Δ-GLP-1, insulin and glucagon responses were abnormal in T2D-H and AGH, respectively. Thus, impaired GLP-1 secretion is unlikely to play a role in islet dysfunction in T2D. Although GLP-1 therapeutics enhance insulin secretion and glucagon suppression, it is likely due to pharmacological amplification of the GLP-1 pathways rather than treatment of hormonal deficiency.
AIMS: Glucagon-like peptide-1 (GLP-1) contributes to insulin secretion after meals. Though Hispanics have increased risk for type 2 diabetes mellitus, it is unknown if impaired GLP-1 secretion contributes to this risk. We therefore studied plasma GLP-1 secretion and action in Hispanic adults. METHODS: Hispanic (H; n = 31) and non-Hispanic (nH; n = 15) participants underwent an oral glucose tolerance test (OGTT). All participants were categorized by glucose tolerance into four groups: normal glucose tolerant non-Hispanic (NGT-nH; n = 15), normal glucose tolerant Hispanic (NGT-H; n = 12), impaired glucose tolerant Hispanic (IGT-H; n = 11), or newly diagnosed type 2 diabetes mellitus, Hispanic (T2D-H; n = 8). RESULTS:Glucose-induced increments in plasma GLP-1 (Δ-GLP-1) were not different in NGT-H and NGT-nH (p = .38), nor amongst Hispanic subgroups with varying degrees of glucose homeostasis (p = .6). In contrast, the insulinogenic index in T2D-H group was lower than the other groups (p = .016). Subjects with abnormal glucose homeostasis (AGH), i.e., T2D-H plus IGT-H, had a diminished glucagon suppression index compared to patients with normal glucose homeostasis (NGT-H plus NGT-nH) (p = .035). CONCLUSIONS:GLP-1 responses to glucose were similar in Hispanic and Non-Hispanic NGT. Despite similar glucose-induced Δ-GLP-1, insulin and glucagon responses were abnormal in T2D-H and AGH, respectively. Thus, impaired GLP-1 secretion is unlikely to play a role in islet dysfunction in T2D. Although GLP-1 therapeutics enhance insulin secretion and glucagon suppression, it is likely due to pharmacological amplification of the GLP-1 pathways rather than treatment of hormonal deficiency.
Authors: Jane Z Kuo; Xiuqing Guo; Ronald Klein; Barbara E Klein; Pauline Genter; Kathryn Roll; Yang Hai; Mark O Goodarzi; Jerome I Rotter; Yii-Der Ida Chen; Eli Ipp Journal: J Clin Endocrinol Metab Date: 2015-05-28 Impact factor: 5.958
Authors: M B Toft-Nielsen; M B Damholt; S Madsbad; L M Hilsted; T E Hughes; B K Michelsen; J J Holst Journal: J Clin Endocrinol Metab Date: 2001-08 Impact factor: 5.958
Authors: T Vilsbøll; F K Knop; T Krarup; A Johansen; S Madsbad; S Larsen; T Hansen; O Pedersen; J J Holst Journal: J Clin Endocrinol Metab Date: 2003-10 Impact factor: 5.958
Authors: S Calanna; M Christensen; J J Holst; B Laferrère; L L Gluud; T Vilsbøll; F K Knop Journal: Diabetologia Date: 2013-02-03 Impact factor: 10.122